Terns Pharmaceuticals Inc (NAS:TERN)
$ 6.01 -1.01 (-14.39%) Market Cap: 388.71 Mil Enterprise Value: 213.81 Mil PE Ratio: 0 PB Ratio: 1.92 GF Score: 40/100

Terns Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript

Jun 13, 2023 / 03:40PM GMT
Release Date Price: $12.29 (+1.99%)
Corinne Jenkins
Goldman Sachs - Analyst

Good morning, everyone, and welcome to our conversation here with Terns Pharmaceuticals. We have Mark Vignola, CFO. We have Erin Quirk, President and Head of R&D. Thanks so much for joining us today.

Maybe first, we could just go with an overview. So if you could give us a brief overview of the pipeline particularly focused on what you see as key value drivers over the next 12 to 24 months.

Erin Quirk
Terns Pharmaceuticals, Inc. - President, Head of Research & Development

Sure, happy to do that. So I'll start off by just saying thanks to the Goldman team and to Corinne for the opportunity here. It's really great to be back here at this conference.

So as you know, Terns is working on three internally discovered compounds of three important mechanisms of action, each of which are clinically validated in three areas of high unmet need overall. So we have TERN-701, our allosteric BCR-ABL inhibitor currently in Phase 1 with our partner Hansoh in China. Hansoh had status update for their ongoing

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot